Universal IbogaineTSXV: IBO
Data updated
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Canadian biotech developing standardised ibogaine therapy protocols for opioid use disorder. Filed a Clinical Trial Application (CTA) with Health Canada for a Phase 1 clinical study. The company has undergone management restructuring and faces ongoing financing challenges.
Clinical Care Delivery Snapshot
Residential & Intensive ProgramsProvider Model
Residential / Intensive Program
Organization Status
Unknown
Psychedelic Services
Multi-Psychedelic Service Offering
Service Coverage
1 country
Service Profile
Care Settings
Service Modalities
Payer Models
Service Coverage Countries
Non-Psychedelic Service Mix
Unknown
Care Delivery Notes
Seeded from user-provided care-delivery.xlsx list. Contacts: Alberto Sola (Co-founder) Contact emails: info@universalibogaine.com Contact phones: 1-855-426-4246
Non-Clinical Facilitation Snapshot
Retreat OrganizationsOrganization Model
Retreat Center Operator
Organization Status
Active
Facilitation Status
Active Facilitation Services
Access Posture
Unknown / Unclear
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Preclinical
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Jan 2026 - Press release - TheNewswire - Ibogaine (Pharmaceutical-Grade) / Ibogaine Programme (OUD) — DISTRESSED / CTA NOT FILED
Next known catalyst
No next milestone forecast yet.
Development Programmes
1Ibogaine (Pharmaceutical-Grade)
IbogaineOpioid use disorder
Opioid Use Disorder (OUD)
Company in financial distress; Management Cease Trade Order (MCTO) from Alberta Securities Commission; CTA was supposed to be filed by Dec 2025 but was NOT; restructuring in progress; Kelburn Recovery Centre temporarily closed
Milestones
Company milestone
CompletedActual: Apr 1, 2024
Engaged Changemark Research + Evaluation Ltd as CRO to compile Health Canada Clinical Trial Application (CTA); 4-6 month expected timeline
Why it matters: CRO engagement for CTA preparation was the first concrete step toward clinical development. GMP ibogaine supply confirmed secured.
Company milestone
CompletedActual: Jan 22, 2025
Sold Belize island property (subsidiary) for USD $300,000 (~CAD $416,000 net); proceeds to fund audit completion and re-engage R&D consultants for CTA
Why it matters: Asset sale to fund basic operations and CTA work indicates severe cash shortage. Selling physical assets to fund regulatory filings is a distress signal.
Company milestone
CompletedActual: Jul 16, 2025
CFO departure; CEO debt settlement via share issuance; board member resignation; two new board members appointed September
Why it matters: Executive turnover and debt-for-equity swaps are hallmarks of corporate distress.
Company milestone
CompletedActual: Sep 4, 2025
Announced intent to file CTA with Health Canada within 90 days; confirmed GMP ibogaine supply secured; selected Intrinsik Corp for regulatory strategy
Why it matters: The 90-day CTA commitment (deadline ~Dec 2025) was NOT met. Despite engaging a regulatory consultant (Intrinsik) and confirming drug supply, the company could not execute the filing.
Company milestone
CompletedActual: Dec 4, 2025
Alberta Securities Commission issued Management Cease Trade Order (MCTO) for failure to file annual audited financial statements
Why it matters: MCTO prevents management from trading securities and signals regulatory non-compliance. Combined with $726,500 in matured convertible debt and the temporary closure of Kelburn Recovery Centre (Winnipeg), the company faces existential risk.
Company milestone
In progressActual: Jan 3, 2026
Bi-weekly default status report: CTA filing postponed until "after restructuring completion"; exploring sale of Kelburn Recovery Centre property; restructuring ongoing
Why it matters: CTA filing indefinitely postponed. The ibogaine clinical programme cannot proceed until the company's financial and regulatory situation stabilizes. High risk of delisting or dissolution.
Watch next: Restructuring completion; MCTO lifting; CTA filing; any acquisition or partnership announcement
Recorded Events
Jan 3, 2026: Company milestone
Dec 4, 2025: Company milestone
Sep 4, 2025: Company milestone
Jul 16, 2025: Company milestone
Jan 22, 2025: Company milestone
Quick Facts
- Type
- Public Biotech
- Ticker
- TSXV: IBO
- Lead Stage
- Preclinical
- HQ
- Canada
- Website
- Visit